Chemicals Beat Can't Escape Consolidated Loss
Bio-chemicals beat guidance and margins expanded, but consolidated net loss of ₹15.2 Cr persists despite 27.5% revenue growth. Sugar and ethanol losses of ₹19.3 Cr EBITDA are consuming profits — the real question is whether debottlenecking can overcome it.
₹204.2 Cr
Beat ₹190 Cr guidance · +38.8% YoY
10.8%
+60 bps YoY · Up from 10.2%
-₹15.2 Cr
Narrowed 63% from -₹41.6 Cr YoY · Still loss
-₹19.3 Cr
Q2 segment drag · Better than -₹23.1 Cr YoY
The split tells the story. Godavari's bio-chemicals business beat guidance by ₹14.2 Cr and expanded margins by 60 basis points — exactly the debottlenecking story management has been selling. But the consolidated result is a loss of ₹15.2 Cr, despite revenue growth of 27.5%. The reason: the sugar and ethanol segment lost ₹19.3 Cr in EBITDA in Q2 alone. Chemicals are roaring; the rest of the business is not just quiet, it's bleeding.
Where the profit went
The sugar and ethanol business is seasonal — management says Q3 and Q4 are typically profitable — but the scale of Q2 loss (₹19.3 Cr EBITDA) is material and ongoing. Sugar revenue fell slightly due to monsoon failure in Maharashtra and Karnataka and government restrictions on diverting sugarcane juice to ethanol. Ethanol, despite a new grain-based distillery commissioned in Q1 (800 kL/day total capacity), faced feedstock constraints and weak pricing. Management expects H2 recovery, but no quantified guidance was offered.
Management claims vs. what holds up
Bio-chemicals revenue ₹204.2 Cr beat ₹190 Cr guidance
Delivered ₹204.2 Cr vs ₹190 Cr; +7.5% beat, +38.8% YoY growth vs ₹147 Cr Q2 FY26
Supported
Bio-chemicals EBITDA margin improved to 10.8%
₹22.1 Cr EBITDA ÷ ₹204.2 Cr revenue = 10.83%; up 60 bps YoY
Supported
Consolidated net loss narrowed to ₹15.2 Cr from ₹41.6 Cr YoY
Q2 FY26 loss -₹41.6 Cr, Q2 FY27 loss -₹15.2 Cr; 63.4% improvement. Still loss, not profit.
Supported (with context)
₹240 Cr quarterly chemicals target by FY28 is achievable
Currently ₹204.2 Cr; requires 17.6% CAGR over ~5 quarters. Dependent on ₹25 Cr capex not yet proven.
Overstated—projection only
Consolidated operations moving toward profitability
Consolidated NPM -2.8% in Q2 FY27. Sugar loss ₹19.3 Cr EBITDA. No PAT timeline disclosed.
Contradicted
What changed on this call
Bio-chemicals beat Q2 guidance by ₹14.2 Cr (₹204.2 vs ₹190 Cr); driven by debottlenecking progress and higher Hormuz-related pricing.
Consolidated loss narrowed 63% YoY but remains -₹15.2 Cr; no path to profitability timeline quantified.
₹240 Cr/qtr chemicals target by FY28 reaffirmed, not raised; same ₹25 Cr capex plan from Q1 guidance.
Grain-based distillery (200 kL/day) now operational; ethanol EBITDA improved to ₹10.6 Cr from ₹4.7 Cr YoY despite feedstock headwinds.
Sugar/ethanol segment loss persists (₹19.3 Cr EBITDA loss Q2) due to monsoon failure and government policy tightening on ethanol diversion.
The bull-bear ledger
Bio-chemicals beat Q2 guidance by ₹14.2 Cr; margins expanded 60 bps; debottlenecking strategy working as expected.
Strong chemicals growth (38.8% YoY) validates market demand for bio-based specialty chemicals; patent portfolio differentiates.
Multi-feedstock distillery (grain + cane) reduces single-feedstock risk; ethanol EBITDA doubled YoY to ₹10.6 Cr.
Near-term catalysts: DME pilot results March 2027, TNBC trials Q3 FY27, 20-25 new specialty chemicals launching April-Sept 2027.
Consolidated loss persists at -₹15.2 Cr despite 27.5% revenue growth; sugar/ethanol loss (₹19.3 Cr EBITDA) is material and ongoing.
No quantified consolidated profitability timeline; management deferred to H2 seasonality and vague ₹240 Cr target without credible path to PAT positive.
Feedstock and government policy volatility (monsoon, sugarcane diversion, grain prices) create headwinds management cannot fully control.
₹240 Cr/qtr target by FY28 is unproven; requires debottlenecking capex to deliver proportional revenue and margin gains.
How the street is positioned
The stock stands at ₹218.06, down 46.63% from its all-time high of ₹408.6 and trading below both the 50-day (₹227.96) and 200-day (₹269.24) moving averages. The trend is bearish; RSI sits at 46.7 (neutral), and volume is decreasing. This is not a stock finding support near its lows — it is a stock that has been rerated lower and lower as consolidated losses accumulated.
Ownership flows confirm the challenge. FII holdings collapsed from 0.98% in FY26 Q4 to 0.22% in FY27 Q1, a drop of 76 basis points in a single quarter. Domestic institutions remain steady at ~10%, and promoters hold firm at 63.31%, but the FII exit is a clear signal: foreign money is not waiting for the consolidated loss story to resolve. Bulk deals over the past six months show research and trading desks accumulating near ₹252 — a tactical trade, not a strategic vote of confidence.
The post-result market reaction appears muted (volume trending lower), suggesting the street views this as neither a relief bounce nor a capitulation flush. The chemicals beat is noted; the consolidated loss is priced in. The real re-rating will come only if management articulates a path to consolidated profitability, or if it delivers on ₹240 Cr chemicals run-rate in real time.
Ranked risks for a holder
Consolidated PAT negative despite 27.5% revenue growth
HighLosses are structural, not cyclical one-offs. No credible timeline to breakeven disclosed. Every quarter of loss erodes shareholder value and constrains capex flexibility.
Sugar/ethanol segment loss-making; feedstock and policy volatility uncontrollable
High₹19.3 Cr EBITDA loss Q2 driven by monsoon, government ethanol restrictions, grain price inflation. H2 recovery promised but not quantified.
Debottlenecking capex and ₹240 Cr target execution uncertain
Medium₹25 Cr capex deployed through 2027 must unlock ₹240 Cr/qtr run-rate. Q2 beat validates progress, but reaching ₹240 Cr requires sustained momentum and new product ramps.
Innovation timelines (DME March 2027, TNBC Q3) may not commercialize as expected
MediumTrials are early-stage; timelines to clinical approval, manufacturing, and revenue uncertain. TNBC is out-licensed (not owned by Godavari).
FII selling and valuation drawdown eroding equity story
MediumFII holders down 76 bps in one quarter; stock down 46% from ATH. Further multiple compression could trigger forced selling if loss persists.
What to watch next
1 · H2 FY27 sugar seasonality and segment turnaround
Management expects Q3/Q4 to be profitable seasonally. Watch for (a) actual sugar revenue and EBITDA in Q3 FY27 results, (b) whether monsoon recovery and improved feedstock availability narrow segment losses, and (c) whether multi-feedstock ethanol facility reduces drag.
2 · ₹25 Cr capex deployment and new specialty chemical ramp
Capex is supposed to unlock 20-25 new specialty chemicals and push bio-chemicals toward ₹240 Cr/qtr. Watch for (a) capex spend progress in FY27 H2, (b) new product launches materializing in April-Sept 2027 window, and (c) revenue contribution visible by Q3/Q4 FY27.
3 · DME pilot and TNBC trial outcomes
DME pilot results due March 2027; TNBC preliminary efficacy due Q3 FY27. Watch for (a) technical feasibility signals, (b) TNBC safety/efficacy data, and (c) out-licensing traction. Disappoint on both and near-term catalysts lose credibility.
The debate
Rating: Hold. For existing holders who believe in the chemicals thesis and can tolerate ongoing quarterly losses. For fresh entry, wait for either (a) a quantified consolidated profitability timeline with a date, or (b) two consecutive quarters of chemicals hitting ₹240+ Cr run-rate while sugar losses materially narrow to ₹5 Cr EBITDA or less. The ₹15.2 Cr consolidated loss is the number to track.
H2 FY27 consolidated net loss is the verdict: if it narrows to ₹10 Cr or less across Q3+Q4, the thesis holds. If it remains above ₹20 Cr, the sugar hedge failed and profitability is pushed to FY28 or later. Watch that number.
Informational and educational content only. Not investment advice.